| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 21/06/24 | GSK | 15:30:00 | 21 Jun 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/06/24 | GSK | 15:30:01 | 12 Jun 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 11/06/24 | GSK | 07:00:08 | 11 Jun 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 10/06/24 | GSK | 18:27:10 | 10 Jun 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 10/06/24 | GSK | 07:00:05 | 10 Jun 2024 | | GSK | FDA approves Arexvy for adults 50-59 at risk | GSK PLC | RNS |
| 03/06/24 | GSK | 15:00:00 | 3 Jun 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 03/06/24 | GSK | 13:03:18 | 3 Jun 2024 | | GSK | Unprecedented results in Jemperli trial continue | GSK PLC | RNS |
| 03/06/24 | GSK | 07:05:00 | 3 Jun 2024 | | GSK | ASCO positive Blenrep DREAMM-8 trial results | GSK PLC | RNS |
| 03/06/24 | GSK | 07:00:08 | 3 Jun 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 24/05/24 | GSK | 07:00:07 | 24 May 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 21/05/24 | GSK | 07:00:11 | 21 May 2024 | | GSK | Positive phase III asthma results for depemokimab | GSK PLC | RNS |
| 20/05/24 | GSK | 15:30:00 | 20 May 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/05/24 | GSK | 07:00:03 | 17 May 2024 | | GSK | GSK completes sale of shares in Haleon plc | GSK PLC | RNS |
| 16/05/24 | GSK | 16:42:36 | 16 May 2024 | | GSK | GSK announces intention to sell shares in Haleon | GSK PLC | RNS |
| 14/05/24 | GSK | 15:30:01 | 14 May 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/05/24 | GSK | 15:00:00 | 13 May 2024 | | GSK | Block listing Interim Review | GSK PLC | RNS |
| 08/05/24 | GSK | 18:21:36 | 8 May 2024 | | GSK | Result of AGM | GSK PLC | RNS |
| 08/05/24 | GSK | 16:57:34 | 8 May 2024 | | GSK | Board Committee Change | GSK PLC | RNS |
| 03/05/24 | GSK | 15:30:00 | 3 May 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 01/05/24 | GSK | 15:00:01 | 1 May 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/05/24 | GSK | 07:00:09 | 1 May 2024 | | GSK | 1st Quarter Results | GSK PLC | RNS |
| 24/04/24 | GSK | 07:00:10 | 24 Apr 2024 | | GSK | US FDA accepts new indication filing for Jemperli | GSK PLC | RNS |
| 19/04/24 | GSK | 15:30:00 | 19 Apr 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/04/24 | GSK | 15:30:00 | 17 Apr 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 17/04/24 | GSK | 07:05:01 | 17 Apr 2024 | | GSK | GSK announces additional EAGLE-1 results | GSK PLC | RNS |
| 17/04/24 | GSK | 07:00:05 | 17 Apr 2024 | | GSK | Results from long-term data relating to Shingrix | GSK PLC | RNS |
| 16/04/24 | GSK | 14:11:09 | 16 Apr 2024 | | GSK | Amendment - Director/PDMR Shareholding | GSK PLC | RNS |
| 16/04/24 | GSK | 07:00:07 | 16 Apr 2024 | | GSK | FDA accepts GSK meningitis vaccine candidate file | GSK PLC | RNS |
| 15/04/24 | GSK | 15:30:01 | 15 Apr 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 04/04/24 | GSK | 12:05:26 | 4 Apr 2024 | | GSK | Replacement - Total Voting Rights | GSK PLC | RNS |
| 02/04/24 | GSK | 15:00:00 | 2 Apr 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 26/03/24 | GSK | 15:30:00 | 26 Mar 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 25/03/24 | GSK | 13:00:00 | 25 Mar 2024 | | GSK | Notice of AGM | GSK PLC | RNS |
| 22/03/24 | GSK | 16:20:40 | 22 Mar 2024 | | GSK | Transfer of Treasury Shares | GSK PLC | RNS |
| 22/03/24 | GSK | 15:36:15 | 22 Mar 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 18/03/24 | GSK | 09:30:00 | 18 Mar 2024 | | GSK | New Phase III Jemperli data in endometrial cancer | GSK PLC | RNS |
| 13/03/24 | GSK | 15:48:43 | 13 Mar 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 08/03/24 | GSK | 17:12:51 | 8 Mar 2024 | | GSK | Board Committee Change | GSK PLC | RNS |
| 07/03/24 | GSK | 07:00:02 | 7 Mar 2024 | | GSK | GSK announces positive Blenrep DREAMM-8 results | GSK PLC | RNS |
| 06/03/24 | GSK | 16:00:00 | 6 Mar 2024 | | GSK | ViiV LAI vs oral SOC data in adherence-challenged | GSK PLC | RNS |
| 05/03/24 | GSK | 17:24:26 | 5 Mar 2024 | | GSK | GSK Annual Report 2023 on Form 20-F | GSK PLC | RNS |
| 05/03/24 | GSK | 07:00:04 | 5 Mar 2024 | | GSK | New ViiV LA formulation potential 4-month dosing | GSK PLC | RNS |
| 01/03/24 | GSK | 15:00:00 | 1 Mar 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/03/24 | GSK | 12:15:33 | 1 Mar 2024 | | GSK | GSK publishes Annual Report 2023 | GSK PLC | RNS |
| 29/02/24 | GSK | 07:05:00 | 29 Feb 2024 | | GSK | Directorate Change | GSK PLC | RNS |
| 29/02/24 | GSK | 07:00:13 | 29 Feb 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 26/02/24 | GSK | 15:30:00 | 26 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 26/02/24 | GSK | 07:00:01 | 26 Feb 2024 | | GSK | GSK announces positive EAGLE-1 headline results | GSK PLC | RNS |
| 22/02/24 | GSK | 15:30:00 | 22 Feb 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
